Chimeric Antigen Receptor Therapy for B-cell Malignancies

David L Porter 1,2 fx, Michael Kalos1,3, Zhaohui Zheng1,3, Bruce Levine1,3, Carl June1,3
1. Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA 2. Division of Hematology-Oncology,
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA 3. Department of Pathology and Laboratory
Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA fx Corresponding author: David L Porter, 3400 Civic Center
Boulevard, PCAM 2 West Pavilion, Philadelphia, PA 19104, Phone 215 662 2862 Fax 215 615 5888 Email david.porter@uphs.upenn.edu

Abstract:

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Key Word:
B-cell Malignancies, CART-19, Chimeric Antigen Receptor Therapy